193 related articles for article (PubMed ID: 11433749)
21. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
22. Clinical study of urine NMP 22 (nuclear matrix protein 22) as a tumor marker in urinary epithelial cancer.
Takeuchi Y; Sawada Y; Yabuki D; Masuda E; Satou D; Kuroda K; Tajima M; Sawamura Y; Matsushima M
Aktuelle Urol; 2003 Jul; 34(4):265-6. PubMed ID: 14566681
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
[TBL] [Abstract][Full Text] [Related]
24. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
Lotan Y; Capitanio U; Shariat SF; Hutterer GC; Karakiewicz PI
BJU Int; 2009 May; 103(10):1368-74. PubMed ID: 19338566
[TBL] [Abstract][Full Text] [Related]
25. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
[TBL] [Abstract][Full Text] [Related]
26. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
[TBL] [Abstract][Full Text] [Related]
28. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
Tritschler S; Scharf S; Karl A; Tilki D; Knuechel R; Hartmann A; Stief CG; Zaak D
Eur Urol; 2007 Feb; 51(2):403-7; discussion 407-8. PubMed ID: 16939699
[TBL] [Abstract][Full Text] [Related]
29. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
30. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
31. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
[TBL] [Abstract][Full Text] [Related]
33. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM; Kiemeney LA; Witjes JA
Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
[TBL] [Abstract][Full Text] [Related]
34. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
Kurokawa S; Morita T; Muraishi O; Tokue A
Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098
[TBL] [Abstract][Full Text] [Related]
35. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
[TBL] [Abstract][Full Text] [Related]
36. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma.
Todenhöfer T; Hennenlotter J; Tews V; Gakis G; Aufderklamm S; Kuehs U; Stenzl A; Schwentner C
Urol Oncol; 2013 Oct; 31(7):1148-54. PubMed ID: 22130125
[TBL] [Abstract][Full Text] [Related]
37. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection.
Miyanaga N; Akaza H; Tsukamoto S; Shimazui T; Ohtani M; Ishikawa S; Noguchi R; Manabe F; Nishijima Y; Kikuchi K; Sato K; Hayashi H; Kondo F; Shiraiwa H; Aoyama O
Int J Clin Oncol; 2003 Dec; 8(6):369-73. PubMed ID: 14663639
[TBL] [Abstract][Full Text] [Related]
39. The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuria.
Trojan B; Tang A; Chandrapal J; Filleur S; Nelius T
Ren Fail; 2013; 35(1):72-6. PubMed ID: 23151051
[TBL] [Abstract][Full Text] [Related]
40. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.
Kaya K; Ayan S; Gokce G; Kilicarslan H; Yildiz E; Gultekin EY
Scand J Urol Nephrol; 2005; 39(1):25-9. PubMed ID: 15764267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
